Valuation: Innoviva, Inc.

Market Cap 1.55B 1.35B 1.25B 1.15B 2.17B 148B 2.2B 14.76B 5.79B 73.56B 5.81B 5.69B 247B P/E 2026 *
6.28x
P/E 2027 * 9.17x
Enterprise Value 1.03B 899M 836M 768M 1.45B 98.68B 1.47B 9.86B 3.87B 49.13B 3.88B 3.8B 165B EV / Sales 2026 *
2.35x
EV / Sales 2027 * 1.69x
Free-Float
99.01%
Yield 2026 *
-
Yield 2027 * -
1 day-1.18%
1 week-2.19%
1 month-7.66%
3 months-8.79%
6 months+4.85%
Current year+4.90%
1 week 20.82
Extreme 20.815
21.95
1 month 20.82
Extreme 20.815
22.73
Current year 19
Extreme 19
25.14
1 year 16.52
Extreme 16.52
25.14
3 years 12.22
Extreme 12.22
25.14
5 years 10.64
Extreme 10.64
25.14
10 years 7.58
Extreme 7.58
25.14
Manager TitleAgeSince
Chief Executive Officer 42 20/05/2020
Director of Finance/CFO 60 21/08/2023
Investor Relations Contact - 01/09/2025
Director TitleAgeSince
Director/Board Member 75 12/02/2018
Director/Board Member 66 12/02/2018
Director/Board Member 42 19/05/2025
Date Insider Type Main position Quantity % Market Cap.
20/5/26 Tax

Chief Executive Officer

-1,130 0.0015%
20/2/26 Tax

Chief Financial Officer

1,244 0.0017%
20/2/26 Tax

Controller/Auditor

2,460 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
-1.18%-2.19%+15.41%+54.76% 1.55B
-0.53%-3.95%+55.23%+152.74% 1,024B
+0.21%-2.68%+55.61%+53.02% 618B
-2.51%-3.25%+32.76%+67.76% 443B
+0.06%-0.42%+37.53%+30.67% 349B
-0.14%-0.24%+34.41%+39.01% 297B
-0.69%-0.30%+11.55%+12.93% 264B
-7.37%-4.40%-2.54%-43.87% 209B
-0.64%+2.43%+30.52%+64.49% 208B
-0.82%+0.70%+15.96%+71.01% 162B
Average -1.36%-1.30%+28.64%+50.25% 357.53B
Weighted average by Cap. -0.99%-1.93%+39.23%+72.95%

Financials

2026 *2027 *
Net sales 441M 383M 356M 327M 618M 42.06B 628M 4.2B 1.65B 20.94B 1.65B 1.62B 70.21B 486M 423M 393M 361M 682M 46.4B 692M 4.64B 1.82B 23.1B 1.83B 1.79B 77.46B
Net income 286M 249M 231M 212M 401M 27.3B 407M 2.73B 1.07B 13.59B 1.07B 1.05B 45.57B 185M 161M 150M 138M 260M 17.67B 264M 1.77B 693M 8.8B 695M 680M 29.5B
Net Debt -514M -447M -416M -382M -721M -49.07B -732M -4.9B -1.92B -24.43B -1.93B -1.89B -81.92B -728M -633M -589M -541M -1.02B -69.54B -1.04B -6.95B -2.73B -34.62B -2.74B -2.68B -116B
Logo Innoviva, Inc.
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Employees
159
Date Price Change Volume
31/07/26 USD 20.97 -1.18% 507,992
30/07/26 USD 21.22 -1.94% 508,588
29/07/26 USD 21.64 -0.78% 536,304
28/07/26 USD 21.81 +2.39% 605,769
27/07/26 USD 21.30 -0.65% 624,274
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
20.97USD
Average target price
35.50USD
Spread / Average Target
+69.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INVA Stock